10 stories mentioning TVRDUpdated 21d ago
Every FINWIRES story that references TVRD, newest first.
Tvardi Therapeutics Inc. (TVRD) has an average rating of overweight and mean price target of $9.75, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Tvardi Therapeutics (TVRD) shares rose more than 52% in Wednesday trading after Raymond James upgraded the stock to outperform from market perform.Trading volume stood at more than 31.6 million shares, compared with a daily average of 1.3 million.Price: $4.69, Change: $+1.59, Percent Change: +51.29%
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.8%.The iShares Biotechnology ETF (IBB) fell 1.5%.In corporate news, Eli Lilly (LLY) is poised to outpace Q2 sales consensus estimates as strong volume uptake of its weight-loss drug Zepbound and Mounjaro diabetes treatment drive franchise performance, RBC said in a note. RBC raised its price target to $1,500 from $1,250. Lilly shares were down 1.2%.AstraZeneca (AZN) and Daiichi Sankyo are in advanced talks with England's drug pricing regulator to make the breast cancer medicine Enhertu available to some patients, Bloomberg reported. AstraZeneca shares were shedding 1.8%.Tvardi (TVRD) said Tuesday its phase 1 study confirmed rapid prodrug conversion of TTI-109 to TTI-101, producing nearly identical plasma levels at molar-equivalent doses, and validating its prodrug design. Raymond James upgraded the stock to outperform from market perform. Shares surged 55%.
Raymond James upgraded the shares of Tvardi Therapeutics (TVRD) to outperform from market perform.Tvardi said Tuesday its phase 1 study confirmed rapid prodrug conversion of TTI-109 to TTI-101, producing nearly identical plasma levels at molar-equivalent doses, and validating its prodrug design. Tvardi plans to advance TTI-109 across dermatologic and gastrointestinal diseases, subject to additional funding.Shares soared 50% as intraday trading volume catapulted to over 20.1 million from a daily average of about 1.32 million.iOThree's (IOTR) shares soared 41% amid heavy trading after the company reported 40% revenue growth, an increase of more than 68% in gross profit, and strong momentum in its edge computing business for the year ended March 31, in a letter to shareholders.Intraday trading volume shot up to over 22.9 million from a daily average of roughly 788,000.Dream Finders Homes (DFH) raised its takeover offer for rival Beazer Homes USA (BZH) to $32 in cash per Beazer share, from the previous cash offer of $29.25 per share submitted in June.Shares of Beazer jumped 16% following an increase in intraday trading volume to over 990,000 from a daily average of about 595,000.Price: $4.62, Change: $+1.52, Percent Change: +49.03%
Tvardi Therapeutics (TVRD) has an average rating of overweight and mean price target of $8.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Tvardi Therapeutics (TVRD) has an average rating of overweight and mean price target of $8.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) decreased 0.4%.In corporate news, Tvardi Therapeutics (TVRD) shares fell 4.1% after Barclays downgraded the company's stock to underweight from equalweight and adjusted the price target to $3 from $4.Eli Lilly (LLY) has agreed to buy clinical-stage biotechnology firm Kelonia Therapeutics for up to $7 billion, as the drugmaker looks to bolster its cancer treatment portfolio. Lilly shares were easing 0.6%.Compass Pathways (CMPS), GH Research (GHRS), and other psychedelic companies' shares were up on Monday, after US President Donald Trump signed an executive order Saturday to expedite access to treatments for patients with serious mental illness. Compass shares surged 42%, and GH Research jumped 17%.Nektar Therapeutics (NKTR) shares climbed 18% after it said Monday that data from a 16-week extension period of its phase 2b study of rezpegaldesleukin showed a "deepening of response" in people with severe-to-very-severe alopecia areata.
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) decreased 0.4%.In corporate news, Tvardi Therapeutics (TVRD) shares fell 4.1% after Barclays downgraded the company's stock to underweight from equalweight and adjusted the price target to $3 from $4.
Tvardi Therapeutics (TVRD) shares were down 4.4% in afternoon trading on Monday after Barclays downgraded the company's stock to underweight from equalweight and adjusted the price target to $3 from $4.Trading volume stood at over 18,000 shares against a daily average of about 54,000.Price: $3.24, Change: $-0.15, Percent Change: -4.42%
Tvardi Therapeutics (TVRD) has an average rating of overweight and mean price target of $8.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
